Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Platform Trial of Novel Regimens vs Standard of Care in NSCLC
2018-001316-29Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Experimental regimen (GSK3359609) with Standard-of-care docetaxel (2 arms). Primary endpoint: Overall survival. Started Dec 2018; status: completed.
02
Drugs
feladilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-001316-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001316-29.